A blog by researchers arguing that clinical trial and regulatory bottlenecks, not just drug discovery, determine how fast AI-driven medical advances reach patients. Posts mix game announcements, commentary on AI hype about curing disease, and explainers of international medicine regulatory reliance pathways.
Website: https://www.clinicaltrialsabundance.blog
PulmCCM covers critical care and pulmonary medicine, with critical appraisals of new trials, regulatory developments, and case-based teaching questions. Readers get detailed breakdowns of study design, results, and limitations, plus CME-oriented learning content.
Junk Charts critiques data visualizations and statistical claims, using frameworks like the Trifecta Checkup to examine charts, data and the questions behind them. Recent issues cover a reproduction of Pfizer Covid-19 vaccine trial analyses, a critique of a subway-stop closure analysis, and a flawed bar chart of top acquisitions.
An oncologist shares lectures and commentary on interpreting cancer clinical trials, including trial design, statistics and conference results. Readers get a critical, clinician's view of how to appraise evidence behind oncology drugs and combinations.
A physician-researcher writes weekly about the science of Parkinson's disease and his own effort to bring a drug candidate (RB-190) into clinical trials. Readers get interpretation of new trial data, personal background, and behind-the-scenes updates on regulatory and drug development work.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
